EXAS241220P42500
- 0.50
- 0.000.00%
Exact Sciences Newsroom
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
Chairman of The Board & CEO of Exact Sciences Picks Up 2.7% More Stock
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Exact Sciences Insider Bought Shares Worth $1,001,325, According to a Recent SEC Filing
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
Express News | Exact Sciences CEO Kevin Conroy Buys 19,500 Shares At $51.35 Each, Investing $1M; Now Holds 1.07M Direct Shares, With Total Holdings Reaching 1.41M Shares Plus 683K Options And Restricted Stock Units
Exact Sciences Corporation (EXAS) Rebounded From the Previous Quarter
Exact Sciences Is Maintained at Overweight by Piper Sandler
Exact Sciences Analyst Ratings
Piper Sandler Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $75
Express News | Exact Sciences Corp : Piper Sandler Cuts Target Price to $75 From $85
Scotiabank Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $70
Exact Sciences Third Quarter 2024 Earnings: Misses Expectations
Exact Sciences (EXAS) Gets a Buy From Wells Fargo
Exact Sciences Poised for Recovery and Long-Term Growth Amidst Challenges
Top Gap Ups and Downs on Wednesday: COIN, CVS, ENPH and More
Exact Sciences Is Maintained at Buy by Jefferies
Express News | Jefferies Maintains Buy on Exact Sciences, Raises Price Target to $85
Exact Sciences Down Over 23%, on Pace for Largest Percent Decrease Since October 2015 -- Data Talk
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount